Molecular Formula | C22H28ClNO2 |
Molar Mass | 373.92 |
Melting Point | 183-185°C (dec.)(lit.) |
Boling Point | 510.5°C at 760 mmHg |
Specific Rotation(α) | D20 -43° (c = 2) |
Flash Point | 262.5°C |
Solubility | H2O: 25mg/mL |
Vapor Presure | 3.02E-11mmHg at 25°C |
Appearance | powder |
Color | white to off-white |
Merck | 14,5551 |
BRN | 3920196 |
Storage Condition | Inert atmosphere,Room Temperature |
Refractive Index | -57.5 ° (C=1, H2O) |
Hazard Symbols | T - Toxic |
Risk Codes | 23/25 - Toxic by inhalation and if swallowed. |
Safety Description | S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | UN 1544 6.1/PG 3 |
WGK Germany | 3 |
RTECS | OJ8490100 |
FLUKA BRAND F CODES | 8 |
Hazard Class | 6.1(b) |
Packing Group | III |
This product is 2 -[l-methyl-6-w hydroxyphenylethyl)-2-pyrazinyl] acetophenone hydrochloride. The content of C222H27N02 • HC1 shall be between 99.0% and 101.5% calculated as dry.
take this product, precision weighing, add water to dissolve and quantitatively dilute to make a solution containing about 10 mg per lml, and determine according to law (General 0621), the specific rotation was -56 ° to -58 °.
take this product, precision weighing, adding water to dissolve and quantitatively dilute the solution containing about 10ug per lml, according to UV-visible spectrophotometry (General 0401) determination, the absorbance was measured at a wavelength of 249mn, and the absorption coefficient was 360 to 390.
take 0.25g of this product, add water to dissolve and dilute to 25ml, the solution should be clear and colorless.
new system for clinical use. Take this product, add the mobile phase to dissolve and dilute to make a solution containing about lmg per lml as the test solution; Take the lml for precision measurement, put it in a 100ml measuring flask, and dilute it to the scale with the mobile phase, as a control solution. According to the high performance liquid chromatography method (General 0512) test, using eighteen alkyl silane bonded silica gel as filler, 0.05mol/L potassium dihydrogen phosphate solution (adjusted to pH 3.0 with phosphoric acid)-methanol (55:45) as mobile phase, the detection wavelength was 210nm. The number of theoretical plates shall not be less than 3000 based on the calculation of Lobeline peak, and the separation degree between Lobeline peak and adjacent peaks shall meet the requirements. 10 u1 of the test solution and the control solution were respectively injected into the human liquid chromatograph, and the chromatogram was recorded to 2.5 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than 0.5 times (0.5%) the area of the main peak of the control solution, and the sum of the areas of each impurity peak shall not be greater than the area of the main peak of the control solution (1.0%).
take this product, put the phosphorus pentoxide dryer to dry to constant weight, weight loss shall not exceed 1.0% (General rule 0831).
not more than 0.1% (General rule 0841).
take this product about 0.3g, precision weighing, add 0.01mol/L hydrochloric acid solution 5ml and ethanol 50ml dissolved, according to the potential titration method (General 0701), with sodium hydroxide titration solution (0.lmol/L) titration, the difference between the two burst point volumes is the titration volume. Each 1 ml of sodium hydroxide titration solution (0.1 mol/L corresponds to 37.39mg of C22H27N02. HCI.
respiratory stimulant.
shade, seal, and store in a cool place.